511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
| Autor: | Vivas, C. Santos, Barrull, J. Vidal, Rodriguez, C. Fernandez, Ballabrera, F. Salvà, Alonso-Orduna, V., Garcia-Carbonero, R., Losa, F., Llavero, N. Tarazona, Aguileria, M.J. Safont, Herrero, F. Rivera, Romero, L. Layos, Morales, M.J. Ortiz, Salud, A., Alcaide-Garcia, J., Paez, D., Hernandez-Yagüe, X., Gallego, R. Alvarez, Vera, R., Paricio, B. Bellosillo, Viladot, C. Montagut |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S433-S434 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|